Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131270 | 0.83 | PDE4A (0.46) | PDE4APDE4BPDE4CPDE4DMRGPRX4 | |
| SCHEMBL3128395 | 0.82 | PPARA (0.50) | PDE4APDE4BPDE4CPDE4DMRGPRX4 | |
| SCHEMBL1159028 | 0.80 | GRM2 (0.44) | PDE4APDE4BPDE4CPDE4DMRGPRX4 | |
| SCHEMBL3129460 | 0.80 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DMRGPRX4 | |
| SCHEMBL3121009 | 0.79 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4DMRGPRX4 | |
| SCHEMBL3123732 | 0.78 | MRGPRX4 (0.44) | PDE4APDE4BPDE4CPDE4DMRGPRX4 | |
| SCHEMBL6070137 | 0.78 | PDE4B (0.42) | PDE4APDE4BPDE4CPDE4DMRGPRX4 | |
| SCHEMBL3129590 | 0.77 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DMRGPRX4 | |
| SCHEMBL3133528 | 0.77 | GRM2 (0.44) | PDE4APDE4BPDE4CPDE4DMRGPRX4 | |
| SCHEMBL3117619 | 0.76 | RXRA (0.41) | PDE4APDE4BPDE4CPDE4DMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | SCHUMACHER RICHARD A | 2006-09-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211865-A1 | Use of pyridine N-oxide analogs at doses which do not induce emesis | PDE4A, PDE4B, PDE3B | PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.